Goldman Sachs Picks 4 Chinese Healthcare Stocks as MSCI China Q2 Earnings Jump 24%
Updated
Updated · CNBC · Sep 13
Goldman Sachs Picks 4 Chinese Healthcare Stocks as MSCI China Q2 Earnings Jump 24%
2 articles · Updated · CNBC · Sep 13
Summary
Goldman Sachs highlighted four Chinese healthcare names—Innovent Biologics, BeOne Medicines, CSPC and Hansoh Pharma—as potential growth plays beyond crowded AI hard-tech trades.
The call follows a sharp earnings rebound: Goldman-tracked Chinese profits rose 24% year over year in the second quarter, up from 6% in the first, with IT and healthcare leading estimate beats.
Healthcare accounted for one-third of Goldman’s 12-stock screen, which targeted buy-rated companies expected to grow earnings more than 15% annually through 2027 and with EPS estimates raised a median 7% in the past month.
Innovent and BeOne are forecast to more than double earnings in the next year, while CSPC is seen growing 26% and Hansoh 15%—all above Goldman’s 8% earnings-growth forecast for MSCI China this year.
That 8% market view remains well below the 17% consensus, underscoring Goldman’s preference for selective stock picking rather than a broad bet on Chinese equities.